EU Case Reports
Journal of Generic Medicines (2008) 5, 229–233. doi:10.1057/jgm.2008.3; published online 11 February 2008
Supplementary protection certificates; atorvastatin; fexofenadine
Compiled and written by Olswang
Olswang is a UK technology law firm providing a comprehensive range of commercial legal services for companies in the pharmaceutical, biotechnology and medical device sectors.
Corporate
Private equity/VC
Public funding/IPO
UK/EU establishment
Banking and finance
Tax
Employment/labour law
Share schemes/employee incentive schemes
Competition/antitrust/regulatory
Intellectual property
Patent, design and trademark filing and prosecution (UK and EU)
Commercial exploitation and collaboration (eg R&D, MTA, NDA, CRADA, JV)
Strategic IP portfolio and advice and management
Freedom to operate/risk analysis opinions
Litigation (UK and EU)
This section summarises and comments on recent interesting judgments. It is not intended to be exhaustive, nor are the papers intended to constitute legal advice. For further information contact:
Michael Burdon
Partner and Head of Biosciences Group
Olswang
90 High Holborn
London WC1V 6XX
UK
Tel: +44 (0)20 7067 3279
Fax: +44 (0)20 7067 3999
Email: Michael.Burdon@olswang.com
www.olswang.com
Michael Burdon1, Robert Stephen2, Priya Vatvani3, Catherine Katzka4 and Luke Hill5
1is a partner at Olswang.
2is a patent attorney at Olswang.
3is a barrister at Olswang.
4is a trainee patent attorney at Olswang.
5is a trainee solicitor at Olswang.
